Stay updated with breaking news from Mark Neumann. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Morgan Stanley initiated coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Get Rating) in a research note released on Thursday, The Fly reports. The brokerage issued an overweight rating and a $80.00 price target on the biopharmaceutical company’s stock. A number of other research analysts have also recently issued reports on the stock. Canaccord Genuity […]
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Rating) was the recipient of a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 3,330,000 shares, an increase of 27.6% from the March 15th total of 2,610,000 shares. Based on an average trading volume of 805,900 shares, the […]
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Rating)’s stock price shot up 2.9% on Friday . The stock traded as high as $61.12 and last traded at $61.00. 288,020 shares traded hands during mid-day trading, a decline of 63% from the average session volume of 785,075 shares. The stock had previously closed at $59.28. Wall Street […]
Should You Buy or Sell Intra-Cellular Therapies Stock? Get The Latest ITCI Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.
Intra-Cellular Therapies (NASDAQ:ITCI – Get Rating) had its price target boosted by Cantor Fitzgerald from $83.00 to $87.00 in a report published on Wednesday, The Fly reports. They currently have an overweight rating on the biopharmaceutical company’s stock. Several other research analysts have also issued reports on the stock. Mizuho lifted their price target on […]